Actuate Therapeutics Inc. (ACTU), a clinical-stage biopharmaceutical company developing therapies for the treatment of difficult-to-treat cancers, has a clinical trial milestone this quarter that could be critical to its future.
The company's lead drug candidate is Elraglusib (formerly 9-ING-41), a Glycogen Synthase Kinase-3 Beta (GSK-3ß) inhibitor. GSK-3ß is an enzyme that plays a role in various cellular functions like cell growth and division. By blocking this enzyme, Elraglusib may help to slow down or stop the growth of cancer cells.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.